TUCSON
520.748.4400
About Us
Professional Staff
Board of Directors
Careers
Contact Us
Frederick Gardner
Cottrell Foundation
Successes
Ventures
Biotechnology
Medical Devices
Other
Historic Investments
Technologies
The CH2 Domain Scaffold – ABDURINS™
Deimmunized Sarcin Ribotoxin
Endotoxin-free ClearColi™ Expression System
Fibronectin Artificial Antibody Scaffold
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Pichia Classic Expression Platform
Pichia GlyoSwitch™ Protein Expression System
Shingles Vaccine Antigen
Ultrasound Tissue Harmonic Imaging
VIMPAT® (lacosamide) for Treatment of Epileptic Seizures
Innovate With Us
News & Events
Home
»
News & Events
»
2017
UCB’s VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
11.6.2017
CDC RECOMMENDS SHINGRIX AS THE PREFERRED VACCINE FOR THE PREVENTION OF SHINGLES FOR ADULTS AGED 50 AND OLDER
10.25.2017
SHINGRIX APPROVED IN THE US FOR PREVENTION OF SHINGLES IN ADULTS AGED 50 AND OVER
10.23.2017
CyMedica Orthopedics® announces FDA clearance for e-vive™, the first app-driven muscle activation therapy and patient engagement solution for pre and post-operative knee surgery rehabilitation
1.17.2017
News by Year
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
From concept
to market
Innovate with us ›